BioDelivery, Meda deal

Meda returned North American rights to Onsolis fentanyl buccal soluble film to BioDelivery. Meda received rights to Onsolis in 2007. BioDelivery plans to re-partner the drug in the U.S. and will work with the FDA to reintroduce Onsolis to the U.S. In 2012, the U.S. relaunch of Onsolis was postponed because of two appearance issues raised by FDA. The financial terms between Meda and BioDelivery allow Meda to share in the proceeds of any new North American partnership for Onsolis. According to BioDelivery, Meda has been focusing on respiratory care in the U.S. (see BioCentury, March 19, 2012 & Sept. 10, 2007). ...